SAM Holdings widens net loss in FY24 on higher finance costs

Loss per share was at $0.0480.

The Singapore Institute of Advanced Medicine (SAM Holdings) reported a net loss of $37.4m in FY24, a 106.6% increase from a net loss of $18.1m in FY23.

It widened losses due to increased finance costs, high depreciation on new proton therapy equipment, and a decline in medical diagnostics revenue amidst strong market competition.

In contrast, the group’s revenue rose by 3% YoY to $16.6m in FY24 driven by growth in radiation therapy and oncology services due to the introduction of its proton beam therapy.

The company's basic and diluted loss per share increased to $0.0480 from $0.0279 in FY23.

Follow the link for more news on

Financial Statements

The people you want to reach are already in this room.

Every quarter, SBR lands on the desks of the founders, CFOs, and directors running Asia's most consequential companies. Every day, they open our newsletter and read our website. It's a room that took twenty years to build — and it's the one most of our partners are trying to get into.

The good news is that the door is open. We work with companies on thought leadership articles, sponsored content, industry summits across Southeast Asia, regional awards programmes, podcasts, and media placements in print and digital. The shape of the right partnership depends on what you're trying to do, which is why we'd rather start with a conversation than send a rate card.

If you have something this room should know about, tell us. We'll tell you honestly whether we can help, and how.

No rate cards until we understand the brief. It's a better use of everyone's time.

Book a meeting

| Or download the media kit (PDF)

240,000 senior readers quarterly in print Top 1,700 Singapore companies reached

7 markets across Southeast Asia